Keywords: new, drugs, cost-effectiveness, independent, assessment, fourth, health

New drugs' cost-effectiveness "needs independent assessment, no fourth

Article | 17 May 2000

Print This

Health outcomes research must not be misused by politicians as a newhurdle for innovative new treatments to undergo in order ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in